Triggered by achieving the initial enrollment target in trial sites in Latin America, Summit Therapeutics (SMMT -5.2%) has earned a $1M milestone payment from licensee Eurofarma Laboratórios SA related to lead candidate ridinilazole for the treatment of Clostridium difficile (C. diff) infection.
The studies are comparing the small molecule antibiotic to standard-of-care vancomycin.
https://seekingalpha.com/news/3539283-summit-therapeutics-earn-1m-milestone-on-advancement-of-ridinilazole
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.